Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 10/20 | 0.76 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.58 |
| ▸ | TNKS | O95271 | 1/20 | 0.57 |
| ▸ | DPP4 | P27487 | 1/20 | 0.56 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.56 |
| ▸ | GRM5 | P41594 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MGAM | O43451 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6083955 | 1.00 | HPGDS (0.76) | HPGDSCXCR4TNKSDPP4DPP7 | |
| SCHEMBL531094 | 0.87 | HPGDS (0.72) | HPGDSCXCR4TNKSDPP4DPP7 | |
| SCHEMBL6084146 | 0.84 | HPGDS (0.59) | HPGDS | |
| SCHEMBL6084135 | 0.84 | HPGDS (0.59) | HPGDS | |
| SCHEMBL6083800 | 0.84 | HPGDS (0.56) | HPGDSGRM5NPC1RAB9ALMNA | |
| SCHEMBL6083797 | 0.84 | HPGDS (0.56) | HPGDSGRM5NPC1RAB9ALMNA | |
| SCHEMBL6085312 | 0.84 | PLK1 (0.61) | HPGDSNPC1RAB9ALMNA | |
| SCHEMBL6085305 | 0.84 | PLK1 (0.61) | HPGDSNPC1RAB9ALMNA | |
| SCHEMBL6085915 | 0.82 | HPGDS (0.83) | HPGDS | |
| SCHEMBL6083947 | 0.82 | HPGDS (0.69) | HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053104-B2 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. (US) | 2006-05-30 | — | — | US | claimed |
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | claimed |
| EP-2672971-A1 | METABOTROPIC GLUTAMATE RECEPTOR GROUP I ANTAGONISTS FOR TREATMENT OF ABNORMAL UNION OF TISSUE | Pharmalundensis AB (SE) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012108831-A1 | METABOTROPIC GLUTAMATE RECEPTOR GROUP I ANTAGONISTS FOR TREATMENT OF ABNORMAL UNION OF TISSUE | REDECO CHEM AB (SE) | 2012-08-16 | — | — | WO | disclosed |
| US-7053104-B2 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | disclosed |
| US-6429207-B1 | QUINOXALINE DERIVATIVES EXHIBITING A HIGH DEGREE OF POTENCY AND SELECTIVITY FOR INDIVIDUAL METABOTROPIC GLUTAMATE RECEPTORS (MGLUR) | NPS PHARMACEUTICALS, INC. | 2002-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | GRM2, GRM1, GRM3 | HPGDS 1409/4885CXCR4 816/4885TNKS 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.